Seres Therapeutics, Inc.MCRB
Price (close)
$3.62
Market cap
$35.6M
P/E
—
Revenue (TTM)
$1.9M
Net income
-$22.5M
Dividend yield
—
1-year total return
-80.8%
Net margin
-1192.9%
Revenue growth
—
Debt / equity
—
What Seres Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $33.2M | $144.9M | $7.1M | $0 | $0 | $789,000 |
| Net income | -$89.1M | -$65.6M | -$250.2M | -$113.7M | $136,000 | $5.7M |
| Free cash flow | -$94.2M | -$2.9M | -$238.6M | -$125.3M | -$149.0M | $865,000 |
More on MCRB.
- Seres Therapeutics, Inc. summary
- Seres Therapeutics, Inc. financial statements
- Seres Therapeutics, Inc. key metrics
- Seres Therapeutics, Inc. health scores and style box
- Seres Therapeutics, Inc. earnings
- Seres Therapeutics, Inc. dividends
- Seres Therapeutics, Inc. valuation
- Seres Therapeutics, Inc. ownership and insiders
- Seres Therapeutics, Inc. peers
Figures from Seres Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.